Meagan A. Jacoby

4.3k total citations
65 papers, 1.3k citations indexed

About

Meagan A. Jacoby is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Meagan A. Jacoby has authored 65 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 19 papers in Molecular Biology and 15 papers in Oncology. Recurrent topics in Meagan A. Jacoby's work include Acute Myeloid Leukemia Research (40 papers), Hematopoietic Stem Cell Transplantation (14 papers) and Acute Lymphoblastic Leukemia research (12 papers). Meagan A. Jacoby is often cited by papers focused on Acute Myeloid Leukemia Research (40 papers), Hematopoietic Stem Cell Transplantation (14 papers) and Acute Lymphoblastic Leukemia research (12 papers). Meagan A. Jacoby collaborates with scholars based in United States, Germany and Australia. Meagan A. Jacoby's co-authors include Samuel H. Speck, Herbert W. Virgin, Keeley D. King, George P. Anderson, Frances S. Ligler, Jay L. Hess, Matthew J. Walter, Scott A. Tibbetts, Jeremy H. Herskowitz and John F. DiPersio and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Meagan A. Jacoby

64 papers receiving 1.3k citations

Peers

Countries citing papers authored by Meagan A. Jacoby

Since Specialization

Citations

This map shows the geographic impact of Meagan A. Jacoby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meagan A. Jacoby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meagan A. Jacoby more than expected).

Fields of papers citing papers by Meagan A. Jacoby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meagan A. Jacoby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meagan A. Jacoby. The network helps show where Meagan A. Jacoby may publish in the future.

Co-authorship network of co-authors of Meagan A. Jacoby

This figure shows the co-authorship network connecting the top 25 collaborators of Meagan A. Jacoby. A scholar is included among the top collaborators of Meagan A. Jacoby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meagan A. Jacoby. Meagan A. Jacoby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes 2024 ·Blood ·Jacqueline S. Garcia, Uwe Platzbecker, Olatoyosi Odenike, (unknown), Chun Yew Fong, Uma Borate, Meagan A. Jacoby, Daniel Nowak, Maria R. Baer, Pierre Péterlin, Brenda Chyla, (unknown), Grace Ku, David Hoffman, Jalaja Potluri, Guillermo Garcia‐Manero	7
2	Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy 2024 ·Blood ·Andrew M. Brunner, Yiwen Liu, Jacqueline S. Garcia, Lourdes Mendez, Catherine Gutierrez, Philip C. Amrein, Rupa Narayan, Rahul S. Vedula, Donna Neuberg, Marcio Andrade‐Campos, Simon Smith, Richard M. Stone, Amir T. Fathi, Matthew J. Walter, Timothy A. Graubert, Meagan A. Jacoby	1
3	Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation 2023 ·Transplantation and Cellular Therapy ·(unknown), Jaebok Choi, Matthew Cooper, (unknown), Mark A. Fiala, Jingxia Liu, Iskra Pusic, Rizwan Romee, Amanda F. Cashen, Meagan A. Jacoby, Keith Stockerl‐Goldstein, Camille N. Abboud, Ravi Vij, Geoffrey L. Uy, Peter Westervelt, Matthew J. Walter, John F. DiPersio, Mark A. Schroeder	2
4	Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation 2023 ·Blood ·Guillermo Garcia‐Manero, Olatoyosi Odenike, Shaun Fleming, Gail J. Roboz, Meagan A. Jacoby, Ilona Cunningham, Karl‐Anton Kreuzer, Anoop Enjeti, Maria R. Baer, Rachel Cook, Joseph G. Jurcic, Grace Ku, Ying Zhou, David Hoffman, Jalaja Potluri, Jacqueline S. Garcia	3
5	A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation 2022 ·Transplantation and Cellular Therapy ·Ramzi Abboud, Feng Gao, Michael P. Rettig, (unknown), Leah Gehrs, Nicholas A. Wallace, Camille N. Abboud, Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matthew Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder	1
6	Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy 2022 ·Haematologica ·Francesca Ferraro, (unknown), Marianna B. Ruzinova, Christopher A. Miller, (unknown), Geoffrey L. Uy, Iskra Pusic, Meagan A. Jacoby, (unknown), Miriam Kim, Peter Westervelt, Amanda F. Cashen, Mark A. Schroeder, John F. DiPersio, Camille N. Abboud, Lukas D. Wartman, Feng Gao, Daniel C. Link, Timothy J. Ley, John S. Welch	7
7	A Pilot Study of CPX-351 (Vyxeos ©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome 2021 ·Blood ·Meagan A. Jacoby, David A. Sallman, Bart L. Scott, (unknown), Fei Wan, John F. DiPersio, Ramzi Abboud, Keith Stockerl‐Goldstein, Rami S. Komrokji, Mark A. Schroeder, Matthew J. Walter, Peter Westervelt, Geoffrey L. Uy	6
8	Inhibition of ATR with AZD6738 (Ceralasertib) for the Treatment of Progressive or Relapsed Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Safety and Preliminary Activity from a Phase Ib/II Study 2021 ·Blood ·Andrew M. Brunner, Yiwen Liu, Lourdes Mendez, Jacqueline S. Garcia, Philip C. Amrein, Donna Neuberg, Emma Dean, Simon A. Smith, Richard M. Stone, Amir T. Fathi, Matthew J. Walter, Timothy A. Graubert, Meagan A. Jacoby	6
9	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS 2021 ·Leukemia Research ·(unknown), Michael P. Rettig, (unknown), Amanda F. Cashen, John F. DiPersio, Feng Gao, Meagan A. Jacoby, Iskra Pusic, Rizwan Romee, Mark A. Schroeder, Geoffrey L. Uy, Stephen Marcus, Peter Westervelt	14
10	A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome 2019 ·Blood ·Andrew H. Wei, Jacqueline S. Garcia, Uma Borate, Chun Yew Fong, Maria R. Baer, Florian Nolte, Pierre Péterlin, Joseph G. Jurcic, Guillermo Garcia‐Manero, Wan‐Jen Hong, Uwe Platzbecker, Olatoyosi Odenike, Martin Dunbar, Ying Zhou, Jason G. Harb, (unknown), Johannes Wolff, Meagan A. Jacoby	39
11	Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma 2017 ·Blood ·John Kuruvilla, Michael R. Savona, Rachid Baz, Morten Mau‐Sørensen, Nashat Gabrail, Ramiro Garzon, Richard M. Stone, Michael Wang, Lynn Savoie, Peter Martin, Ian W. Flinn, Meagan A. Jacoby, Thaddeus J. Unger, Jean-Richard Saint-Martin, Tami Rashal, Sharon Friedlander, Robert Carlson, Michael Kauffman, Sharon Shacham, Martin Gutierrez	112
12	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen 2017 ·Cancer Medicine ·Alaa M. Ali, (unknown), Feng Gao, Geoffrey L. Uy, Amanda F. Cashen, Meagan A. Jacoby, Lukas D. Wartman, Armin Ghobadi, Iskra Pusic, Rizwan Romee, Todd A. Fehniger, Keith Stockerl‐Goldstein, Ravi Vij, Stephen T. Oh, Camille N. Abboud, Mark A. Schroeder, Peter Westervelt, John F. DiPersio, John S. Welch	21
13	Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant 2017 ·Blood ·Meagan A. Jacoby, Eric J. Duncavage, Gue Su Chang, Christopher A. Miller, Jin Shao, (unknown), Joshua D. Robinson, Robert S. Fulton, Catrina C. Fronick, Michelle D. O’Laughlin, Daniel C. Link, John F. DiPersio, Peter Westervelt, Timothy J. Ley, Timothy A. Graubert, Matthew J. Walter	1
14	A Pilot Study of CX-01 with Azacitidine for Treatment of Hypomethylating Agent-Refractory AML and MDS 2017 ·Blood ·(unknown), Amanda F. Cashen, John F. DiPersio, Meagan A. Jacoby, Iskra Pusic, Rizwan Romee, Geoffrey L. Uy, Peter Westervelt	3
15	A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome 2016 ·Leukemia & lymphoma ·Mathew Cherian, Raoul Tibes, Feng Gao, Theresa Fletcher, Mark A. Fiala, Geoffrey L. Uy, Peter Westervelt, Meagan A. Jacoby, Amanda F. Cashen, Keith Stockerl‐Goldstein, John F. DiPersio, Ravi Vij	8
16	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation 2016 ·Leukemia Research ·Armin Ghobadi, Jaebok Choi, Mark A. Fiala, Theresa Fletcher, Jingxia Liu, Linda Eissenberg, Camille N. Abboud, Amanda F. Cashen, Ravi Vij, Mark A. Schroeder, Iskra Pusic, Keith Stockerl‐Goldstein, Meagan A. Jacoby, Geoffrey L. Uy, John F. DiPersio, Peter Westervelt	33
17	Implications of Tumor Clonal Heterogeneity in the Era of Next-Generation Sequencing 2015 ·Trends in cancer ·Meagan A. Jacoby, Eric J. Duncavage, Matthew J. Walter	23
18	Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen 2013 ·Biology of Blood and Marrow Transplantation ·(unknown), (unknown), Keith Stockerl‐Goldstein, John F. DiPersio, Geoffrey L. Uy, Peter Westervelt, Jingxia Liu, Mark A. Schroeder, Ravi Vij, Camille N. Abboud, Todd A. Fehniger, Amanda F. Cashen, Iskra Pusic, Meagan A. Jacoby, (unknown), Rizwan Romee	71
19	Detection of copy number alterations in acute myeloid leukemia and myelodysplastic syndromes 2012 ·Expert Review of Molecular Diagnostics ·Meagan A. Jacoby, Matthew J. Walter	12
20	Detecting wildlife orthologues for tumor necrosis factor (TNF) and interleukin-6 (IL-6) 2000 ·Northwest Science ·G. Bolgos, Daniel G. Remick, Douglas R. Call, Meagan A. Jacoby, Karin Rudolph, (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact